Delinking the cost of R&D from the final prices of medicines and making governments the funders and planners of drug development would be rife with problems.
August 24, 2018
A contagion of poor public policy is sweeping across Latin America in the form of the spreading use of compulsory licenses on novel pharmaceutical drugs, and it threatens to undermine the very ecosystem supporting the development of medicines designed to treat deadly diseases in the first place.
July 30, 2018
Fact of the Week: The Cost To Sequence a Human Genome Decreased More than 99.999 Percent Between 2000 and 2016
The future of medicine lies in better understanding the human genome and how our bodies function at the most basic level, and that requires reliable and inexpensive genome sequencing. Technological breakthroughs, such as fluorescent labelling and programs capable of reconstructing smaller DNA fragments, massively decreased costs of a full genome sequence to from $300 million in 2000 to $1,500 in 2016.
June 28, 2018
As ITIF’s Stephen Ezell and Richard Owens of the Macdonald Laurier Institute write for the Financial Post, free-riding on drug prices is an example of how Canada refuses to step up to what is required for a globally leading innovation culture.
June 18, 2018
Fact of the Week: If Drug Price Controls Were Lifted Throughout the OECD, the Number of new Treatments Available Would Increase 9 to 12 Percent by 2030
If drug price controls were lifted throughout the OECD, the number of new treatments available would increase 8 to 13 new drug compounds by 2030, writes John Wu in Innovation Files.
May 9, 2018
Please join ITIF for an event discussing needed policies to ensure sustained U.S. life-sciences leadership.
May 7, 2018
Any effective U.S. life-sciences innovation policy needs to level the global playing field by taking more forceful action to address unfair trade practices, Joe Kennedy writes for Stat News.
April 30, 2018
Intellectual property rights go a long way to helping transform clever ideas into life-saving products that address global health challenges, ITIF’s Stephen Ezell and Mark Schultz of the Southern Illinois University School of Law write for Brink News.
April 24, 2018
Twenty-five case studies underscore how innovators in developing countries—often enabled by robust IP rights—are achieving advances in life sciences and healthcare that benefit people around the world.
April 24, 2018
Please join ITIF and the Center for the Protection of Intellectual Property for an event releasing a new report that documents 25 cases of primarily developing-world entrepreneurs meeting global health challenges by “innovating for health.” The event will discuss what policies, including intellectual property, are needed to underpin successful life-sciences innovation in both the developed and developing world and feature presentations from several developing-country healthcare innovators who are leveraging IP, science, and technology to create a better world.
March 26, 2018
America’s lead in life sciences is being challenged. Other countries are aggressively seeking to attract and grow companies with innovation-based tax incentives, a range of firm-specific enticements, increased government research funding, improved IP protections, and streamlined regulatory approval processes. The federal government should act to ensure U.S. life sciences remain competitive.